A Case Presentation of Gastrointestinal Stromal Tumor of Duodenum by Ghazanfar, Aamir et al.
 Journal of Renal and Hepatic Disorders 2021;5(1): 49–53 49
Journal of  Renal and Hepatic Disorders
HEPATIC DISORDERS
A Case Presentation of Gastrointestinal Stromal Tumor  
of Duodenum
Aamir Ghazanfar1, Afifa Asghar1, Farrukh Zaman1, Hassan Mumtaz1, Shahzeb Habib1,  
Shahzaib Ahmad2
1KRL Hospital, Islamabad, Pakistan; 2King Edward Medical University Lahore, Pakistan
Abstract
A gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. It is caused by the mutation 
in KIT and PDGFRα genes. It constitutes <1% of all gastrointestinal tumors. Duodenal GISTs constitute 4.5% of all GISTs. We report a 
61-year-old lady, presented with generalized abdominal pain, vomiting, abdominal distension, and nausea for the last 3 years. Physical exam-
ination showed a pallor and on abdominal examination, a large palpable mass was extending from the pelvis to the right upper quadrant of the 
 abdomen. The CT scan showed a large heterogeneously echogenic mass in the abdomen and pelvis with no lymphadenopathy and distant metas-
tasis in this region. Laparotomy showed a large globular mass extending from the pelvis to the right upper quadrant of the abdomen adherent to 
the wall of a third part of the duodenum. Complete surgical resection of tumor done with an intact capsule. Microscopic examination showed 
neoplastic spindle cells with tumor necrosis. An immunohistochemical study confirmed GIST.
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Introduction
Gastrointestinal stromal tumors (GISTs) are the most com-
mon mesenchymal tumors of the gastrointestinal tract (1,2). 
They constitute <1% of all gastrointestinal tract malignan-
cies (3). Duodenal GISTs constitute 4.5% of all GISTs  (4). 
GIST of the duodenum is rare than other parts of the 
small intestine. Around 3300 to 6000 new cases of GISTs 
are reported per year in the United States (5). Surveillance, 
Epidemiology and End Result (SEER) data estimated six 
to eight cases of GISTs per million of the population from 
1992 to 2000 (6). In the past, GISTs and leiomyosarcoma 
were considered as the same entity but now it is revealed 
that GISTs are CD34 immunoreactive and express tyrosine 
kinase c-KIT CD117 receptor activity (7).
Case presentation
A 61-year-old diabetic lady, presented with generalized 
abdominal pain, which was gradual in onset, moderate to 
severe in intensity, associated with nausea, vomiting, and 
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abdominal distention. There were no symptoms of diar-
rhea, constipation, anorexia, weight loss, jaundice, hemate-
mesis, melena, and per rectal bleed. There was no family 
history of malignancy. The patient was in a usual state of 
health 3 years ago when she had complained of pain in the 
right upper quadrant which was moderate to severe in inten-
sity, non-radiating, with no aggravating or relieving factors, 
associated with high-grade fever with rigors and chills. The 
patient had visited multiple hospitals where she was treated 
conservatively.
The patient had no compliance with that treatment. 
General physical examination showed pallor with no other 
remarkable finding. The cardiopulmonary examination was 
unremarkable. Abdominal examination revealed a large, 
non-tender palpable mass extending from the pelvis to the 
right upper quadrant.
Complete blood picture showed normocytic and normo-
chromic anemia with Hb concentration of 10.3 g/dL (8–12), 
HCT 31.5% (40–50), MCV 87 fL (82–98), MCH 28.5 pg 
(27–31), MCHC 32.7 g/dL (32–36) with total RBC count 
3.62 millions/mL (4.5–6), TLC count of 16160/mm3, and 
adequate platelet count. RBC morphology showed micro-
cytosis, anisocytosis, and hypochromia. ESR of 67 mm/1st 
hour (0–20).
Other tests like liver function tests, renal function tests, 
serum amylase, coagulation profile, urine routine examina-
tion, TSH, CA-125, β-HCG, and alpha-fetoprotein were 
found normal.
Abdominal ultrasound showed a significant increase in the 
size of the mass on the right side of the abdomen as com-
pared to the previous report. CT scan of abdomen and pel-
vis showed a large (18×10×5 cm) heterogeneously enhancing 
mass in abdomen and pelvis with fairly well-defined margins, 
displacing abdominal and pelvic viscera.
Inferiorly it was inseparable from right adnexal structures 
and closely abutting the dome of the urinary bladder. Fat 
planes between this mass lesion and gastric pylorus and the 
first part of the duodenum were indistinct. There were no 
ascites, lymphadenopathy, lung base or abdominopelvic vis-
ceral and bony metastasis.
Laparotomy with midline incision showed a large globu-
lar, irregular, encapsulated mass measuring 20 × 18 ×10.5 cm 
extending from the pelvis to the right upper quadrant of the 
abdomen and attached to the wall of a third part of the duo-
denum. Mass was not adherent to adnexa and multiple areas 
of cystic hemorrhagic foci were visible on its surface. No 
local invasion, lymphadenopathy, or distant metastasis were 
seen in this region as shown in Figure 1. Complete surgical 
resection of the tumor with intact capsule is done as shown 
in Figure 2.
The patient remained hospitalized for 5 days and was dis-
charged 2 days after the surgery. A cut section of the speci-
men showed tan, white, fragile mass containing hemorrhagic 
foci. Microscopic examination of sections revealed a lesion 
composed of haphazardly arranged fascicles and sheets of 
spindle cells as shown in Figure 3.
The individual cells have abundant cytoplasm and elon-
gated nuclei with coarse chromatin. Scattered within the 
lesion are areas of necrosis as shown in Figure 4. 
Immunohistochemical staining performed which showed 





CD 117  Positive
Vimentin Positive
Diagnosis: Gastrointestinal stromal tumor of the duodenum.
CT scan of abdomen and pelvis with contrast is advised tri-
monthly for 1 year, 6 monthly for 5 years, and then yearly.
Figure 1: Grossly large gastrointestinal stromal tumor with 
irregular borders and encapsulated.
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Figure 2: GIST exhibits a solid, sometimes cystic fleshy 
tumor with multiple hemorrhagic foci.
Figure 3: Spindle cells showing interlacing pattern. The indi-
vidual cells have abundant cytoplasm and elongated nuclei 
with coarse chromatin.
Figure 4: Scattered within the lesion are areas of tumor 
necrosis seen.
Discussion
Gastrointestinal stromal tumors are mesenchymal tumors of 
the gastrointestinal tract (1). They are located in the submu-
cosa of the gastrointestinal tract (2). Differentials of GIST 
are leiomyosarcoma of the intestine, dermoid cyst, mesen-
teric cyst, retroperitoneal mass, or exophytic mass from gas-
trointestinal origin. GISTs are <1% of all gastrointestinal 
malignancies (3). Duodenal GISTs constitute 4.5% of all 
GISTs (4). It was first found that GISTs originate from the 
interstitial cell of Cajal which are located in the myenteric 
and submucosal plexus of the gastrointestinal tract but it is 
now attributed to multipotential mesenchymal stem cell (19).
In the past, GISTs, leiomyoma, and leiomyosarcoma were 
considered as the same entity because GISTs also possessed 
smooth muscle features under light microscopy but now 
with the advancement in diagnostic modalities, it is revealed 
that GISTs are CD 34 immunoreactive and express tyrosine 
kinase c-KIT (CD 117) receptor activity (7).
The cause of GISTs is mutation in either KIT or  PDGFR-α 
(Platelet-derived growth factor receptor α) gene (9–11). The 
annual incidence of GISTs is 10–20 per million per year with 
a 20%–30% possibility of malignancy. GISTs are more com-
mon above the age of 50 years with a median age range of 
55–65 years. Some of the studies show same gender distribu-
tion but most of the studies show male predominance (20).
The commonest site of occurrence of GISTs is the stom-
ach (50%–60%). Other sites are the small intestine (30%–
40%), duodenum (4.5%), and 5% in the colon, rectum, and 
esophagus. Other rare sites are mesentery and omentum (9).
Seventy percent of patients with GISTs are symptomatic, 
20% remain asymptomatic, and 10% are detected at autopsy. 
Fifty percent of patients with GIST have already been metas-
tasized at the time of diagnosis. Microscopically, GISTs of 
the small intestine are more often spindled than epithelioid 
and are eosinophilic, composed of collagen with Periodic 
Acid Schiff  stain positive (10).
One of the studies on the clinical analysis of primary 
small intestinal diseases shows the major clinical symptoms 
include abdominal pain (71%), abdominal mass (14%), 
vomiting (10%), melena (10%), and fever (10%) (11). GISTs 
metastasize homogeneously. Lymph node metastasis is very 
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GIST is better than small intestine GIST. The recurrence rate 
is high, so regular follow-up is necessary. 
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9. Daumová M, Vaňková B, Švajdler Met al. 
Immunohistochemistry and molecular genetics in the differen-
tial diagnostics of mesenchymal lesions of gastrointestinal tract. 
Cesk Patol. 2020;56(4):212–20. PMID: 33736442.
10. El-Menyar A, Mekkodathil A, Al-Thani H. Diagnosis and man-
agement of gastrointestinal stromal tumors: An up-to-date liter-
ature review. J Cancer Res Ther. 2017;13(6):889–900. https://doi.
org/10.4103/0973-1482.177499. PMID: 29237949.
11. Weerts ZZRM, Masclee AAM, Witteman BJM, et al. Efficacy 
and safety of peppermint oil in a randomized, double-blind trial 
of patients with irritable bowel syndrome. Gastroenterology. 
2020;158(1):123–36. Epub 2019 Aug 27. PMID: 31470006.
https://doi.org/10.1053/j.gastro.2019.08.026
12. Søreide K. Cancer biology of small gastrointestinal stromal 
tumors (<2 cm): What is the risk of malignancy? Eur J Surg 
rare (12). The size of GISTs varies from few millimeters to 
more than 30 cm. Macroscopically, GISTs mostly present 
as an exophytic mass that is attached to the gastrointestinal 
tract (stomach or small intestine) in the abdominal cavity 
and displacing other organs (14).
Diagnostic modalities include Barium examination of 
the gastrointestinal tract, CT scan, and EUS guided FNAC 
which has 80%–85% accuracy but with considerable risk of 
tumor rupture and dissemination (15).
Tumor size >5 cm with extraluminal growth, irregu-
lar borders, and heterogeneous have malignant potential. 
Immuno histochemistry is a very important investigation that 
differentiates GISTs from leiomyosarcoma as GISTs are CD 
117 positive in 80%–85% of cases (16).
The most important predictor of malignancy is size and 
mitotic rate. Tumor with size ≤2 cm and ≤5 mitosis per 50 
high power field (HPF), shows low risk and good progno-
sis. Tumor having a size range ≥5 cm with ≥5 mitosis per 50 
HPF shows high risk. Tumors of the small intestine with size 
>5cm are considered aggressive regardless of mitotic index. 
The median survival of the patient with fully resected tumor 
patient is 66 months and for locally advanced and metastatic 
tumor median, survival is 9–20 months. Two years survival 
after imatinib mesylate therapy is 70– 50% (17).
The most effective treatment is surgical resection with 
avoidance of tumor rupture because it is associated with an 
increased risk of peritoneal implantation. GISTs are resis-
tant to standard chemotherapy. Imatinib mesylate is used in 
advanced and metastatic GISTs but the use of adjuvant ima-
tinib therapy after complete resection of the tumor is under 
evaluation (18).
Stromal tumors have highly variable growth features which 
include tumors with intra or transmural, intraluminal, and 
pedunculated appearances. Clinical presentation depends 
on size, growth pattern as well as on the site of the tumor. 
Stromal tumor in the stomach has the lowest rate of acute 
and emergency symptoms with 31%, whereas the duodenum 
has 42%, followed by small bowel having acute symptoms of 
more than 50% (21). The intestinal tumors are found to be of 
high grade (70%) and high-risk prognostic group (75% and 
80%) as compared to stomach GISTs (43% of highrisk prog-
nostic group) (22).
The majority of GISTs recur in 3–5 years period. Accord-
ing to National Comprehensive Cancer Network Guidelines, 
a CT scan of the abdomen and pelvis with contrast is recom-
mended 3–6 monthly for 3–5 years and then yearly (23).
Conclusions
Gastrointestinal stromal tumors can be resected surgically 
with its capsule being intact in order to avoid peritoneal 
implantations. Imatinib mesylate therapy is used for locally 
advanced and metastatic tumor. The prognosis of high-risk 
Gastrointestinal stromal tumor involving duodenum
 Journal of Renal and Hepatic Disorders 2021;5(1): 49–53 53
Oncol. 2017;43(7):1344–9. Epub 2017 Feb 9. PMID: 28222971.
https://doi.org/10.1016/j.ejso.2017.01.240
13. Tryggvason G, Hilmarsdottir B, Gunnarsson GH, et al. Tyrosine 
kinase mutations in gastrointestinal stromal tumors in a nation-
wide study in Iceland. APMIS. 2010;118(9):648–56. PMID: 
20718716. https://doi.org/10.1111/j.1600-0463.2010.02643.x
14. Zhang JQ, Zeng S, Vitiello GA, et al. Macrophages and CD8+ T 
cells mediate the antitumor efficacy of combined CD40 ligation 
and imatinib therapy in gastrointestinal stromal tumors. Cancer 
Immunol Res. 2018;6(4):434–47. Epub 2018 Feb 21. PMID: 
29467128; PMCID: PMC6203303. https://doi.org/10.1158/2326-
6066.CIR-17-0345 
15. Trindade AJ, Benias PC, Alshelleh M, et al. Fine-needle biopsy 
is superior to fine-needle aspiration of suspected gastrointes-
tinal stromal tumors: a large multicenter study. Endosc Int 
Open. 2019;7(7):E931–6. Epub 2019 Jul 11. PMID: 31304239; 
PMCID: PMC6624113. https://doi.org/10.1055/a-0953-1640
16. Hansen T, Titze U, Trachte F, et al. [Uncommon tumor of 
the gastric wall]. Pathologe. 2020 Dec 23. German. Epub 
ahead of print. PMID: 33355706. https://doi.org/10.1007/
s00292-020-00886-6
17. Kanda T, Masuzawa T, Hirai T, et al. Surgery and imatinib 
therapy for liver oligometastasis of GIST: A study of Japanese 
Study Group on GIST. Jpn J Clin Oncol. 2017;47(4):369–72. 
PMID: 28073945. https://doi.org/10.1093/jjco/hyw203
18. Nagami Y, Ominami M, Otani K, et al. Endoscopic submu-
cosal dissection for adenocarcinomas of the esophagogastric 
junction. Digestion. 2018;97(1):38–44. Epub 2018 Feb 1. PMID: 
29393168. https://doi.org/10.1159/000484111
19. Mantese G. Gastrointestinal stromal tumor: Epidemiology, 
diagnosis, and treatment. Curr Opin Gastroenterol. 
2019;35(6):555–59. PMID: 31577561. https://doi.org/10.1097/
MOG.0000000000000584
20. Park J, Yoo HM, Sul HJ, et al. Genetic characterization of 
molecular targets in Korean patients with gastrointestinal stro-
mal tumors. J Gastric Cancer. 2020;20(1):29–40. Epub 2019 
Dec 27. PMID: 32269842; PMCID: PMC7105413. https://doi.
org/10.5230/jgc.2020.20.e2 
21. Menge F, Jakob J, Kasper B, et al. P. Clinical presentation of 
gastrointestinal stromal tumors. Visc Med. 2018;34(5):335–40. 
Epub 2018 Oct 13. PMID: 30498699; PMCID: PMC6257088. 
https://doi.org/10.1159/000494303
22. Hashmi AA, Faraz M, Nauman Z, et al. Clinicopathologic fea-
tures and prognostic grouping of gastrointestinal stromal tumors 
(GISTs) in Pakistani patients: An institutional perspective. 
BMC Res Notes. 2018;11(1):457. PMID: 29996918; PMCID: 
PMC6042430. https://doi.org/10.1186/s13104-018-3562-8
23. Gronchi A, Bonvalot S, Poveda Velasco A, et al. Quality of sur-
gery and outcome in localized gastrointestinal stromal tumors 
treated within an international intergroup randomized clinical 
trial of adjuvant imatinib. JAMA Surg. 2020;155(6):e200397. 
Epub 2020 Jun 17. PMID: 32236507; PMCID: PMC7113837. 
https://doi.org/10.1001/jamasurg.2020.0397
